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A B S T R A C T

The vast majority of patients in the ongoing coronavirus Disease 2019 (Covid-19) pandemic primarily present with severe respiratory illness. We report a Covid-19 patient who presented with ﬁndings of acute coronary syndrome and was found to have purulent fulminant myopericarditis and cardiac tamponade.
We compare our case to the previously reported instances of Covid-19-associated myocarditis. Through
review of the available literature, we also highlight the potential mechanisms of cardiac injury in Covid-19.
We hope to increase awareness amongst clinicians about this unusual presentation of Covid-19.
© 2020 Elsevier Inc. All rights reserved.

Introduction
In December 2019, the World Health Organization (WHO) was
notiﬁed about multiple cases of pneumonia of unknown etiology
originating in Wuhan city, Hubei province, China. The novel virus,
named severe-acute-respiratory-syndrome-coronavirus-2 (SARSCov-2) was isolated on January 7th, 2020.1 The acute respiratory disease, renamed Coronavirus Disease 2019 (Covid-19), was declared a
pandemic on March 11th, 2020.2
SARS-Cov-2 has been seen to produce primarily respiratory symptoms, with evidence of ground-glass opacities on chest imaging.3
However, the cardiovascular effects of SARS-Cov-2 have not been
fully characterized.4
We report a patient with Covid-19 who presented with ﬁndings of
acute coronary syndrome and was found to have purulent fulminant myopericarditis and cardiac tamponade, with subsequent circulatory shock.
Case report
A 50-year-old gentleman presented to an outside hospital with
fevers, chills, generalized malaise, non-productive cough, dyspnea for
Abbreviations:
SARS-Cov-2,
severe-acute-respiratory-syndrome-coronavirus-2;
Covid-19, coronavirus disease 2019
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3 4 days and an episode of near-syncope on the day of presentation.
In the emergency department, he was intubated for acute hypoxemic
respiratory failure and SARS-Cov-2 testing was positive. ST-segment
changes were noted on the electrocardiogram (ECG), so he was transferred to our hospital for acute coronary syndrome (ACS) management.
Past history was signiﬁcant for hypertension and ischemic stroke.
He was born in Honduras and immigrated to the United States at age
twelve. There was no documented history of recent travel or sick contacts.
Admission labs were signiﬁcant for leukocytosis with lymphopenia [white blood cell count 19,290/mL, absolute lymphocyte count
850/mL]; sodium 115 mEq/L; chloride 75 mEq/L; bicarbonate
13 mEq/L; anion gap 27; acute kidney injury (AKI) [blood urea nitrogen 44 mg/dL, creatinine 3.56 mg/dL]; elevated transaminases [aspartate transaminase (AST) 70 U/L, alanine transaminase (ALT) 48 U/L];
lactate dehydrogenase (LDH) 3332 U/L; arterial lactate 4 mmol/L.
Arterial blood gas analysis revealed pH 7.21, pCO2 67mm Hg, pO2
213mm Hg on mechanical ventilator support (FiO2 80%, PEEP 10cm
H2O). Reverse-transcriptase-polymerase-chain-reaction test of a
nasopharyngeal specimen reconﬁrmed SARS-Cov-2 infection.
Chest radiography revealed diffuse bilateral patchy opacities
(Fig. 1). ECG showed sinus tachycardia, ST-elevation in leads II, III,
aVF and ST-depression in I, aVL. Cardiac markers were elevated: high
sensitivity troponin 544 ng/L, creatine kinase 2135 U/L, creatine
kinase myocardial band 54.3 ng/mL. Other inﬂammatory markers
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Fig. 1. Portable chest radiograph (Antero-posterior view) showing presence of diffuse bilateral patchy opacities within lung parenchyma. The cardiac silhouette appears normal in
size. An endotracheal tube is visualized (blue arrow), with the tip above the carina. An enteric tube is noted (yellow arrow), with its distal end coursing below the diaphragm. A femoral approach Swan-Ganz catheter is noted (green arrow), with its tip overlying the right pulmonary artery. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.).

were also signiﬁcantly elevated: erythrocyte sedimentation rate was
46 mm/hr, D-dimer 1068 ng/mL D-dimer units, procalcitonin 8.16 ng/
mL, C-reactive protein 11.85 mg/dL, ferritin 66,165 ng/mL. T-cell subset analysis showed absolute CD4+ count 285/mL (26%) and CD8+
count 114/mL (10%).
On arrival, he was immediately taken to the cardiac catheterization laboratory (CCL). Coronary angiography revealed right dominant

circulation with normal coronary vessels. Transthoracic echocardiogram (TTE) showed severe global left ventricular systolic dysfunction,
right ventricular (RV) enlargement, RV systolic dysfunction. A moderate-to-large pericardial effusion was noted anterior to the RV with
organizing material (suggesting an inﬂammatory process). There was
evidence of intermittent RV impaired ﬁlling and collapse, suggestive
of tamponade physiology (Fig. 2).

Fig. 2. Echocardiographic image (subcostal view) showing large pericardial effusion (red arrow) producing cardiac tamponade and collapse of right ventricle (blue arrow). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.).
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Table 1
Patient characteristics
Key: AKI: acute kidney injury; ALC: absolute lymphocyte count; ALT: alanine transaminase; BALF: bronchoalveolar lavage ﬂuid; BNP:
brain natriuretic peptide; CRP: C-reactive protein; CK: creatine kinase 2135 U/L; CK-MB: creatine kinase myocardial band; CRRT: continuous renal replacement
therapy; CVA: cerebrovascular accident; DDU: D-dimer unit; DOHS: day of hospital stay; ECMO: extracorporeal membrane oxygenation; ESR: erythrocyte sedimentation rate; HCQ: hydroxychloroquine; hsT: high sensitivity troponin; HTN: Hypertension; IABP: intra-aortic balloon pump; IVIG: intravenous immune
globulin; LDH: lactate dehydrogenase; LV: left ventricle; LVEF: left ventricular ejection fraction; MP: methylprednisolone; MV: mechanical ventilator support;
NP-PCR: nasopharyngeal polymerase chain reaction; ntBNP: n-terminal brain natriuretic peptide; PCR: polymerase chain reaction; RV: right ventricle; tropI:
troponin I; WBC: white blood cell count.

Age/Sex
Comorbidities

Case 1
50/M
HTN CVA

Travel History

Unknown

Symptoms

Radiographic
ﬁndings

1. Fever, chills
2. Generalized malaise
3. Non-productive
cough
4. Dyspnea
5. Near-syncope
Diffuse bilateral
patchy opacities

Initial cell counts
(/mL)
Initial Laboratory
abnormalities

Initial Inﬂammatory
markers

Initial Cardiac
markers

Case 2
63/M
Prior smoker Allergic cough
Hubei Province,
China
1. Fever
2. Productive cough
3. Dyspnea and
chest tightness
after exertion

Case 3
Case 4
64/F
53/F
HTN Hyperlipidemia None

Case 5
37/M
None

Not reported

Unknown

Unknown

Persistent chest
pressure

1. Fever
2. Cough
3. Fatigue

1. Chest pain
2. Dyspnea
3. Diarrhea

1. Subjective fevers
2. Non-productive
cough
3. Chest pain
4. Dyspnea

Ground-glass
opacities

No acute
abnormalities

No acute
abnormalities

Mild pulmonary
congestion

WBC: 19,290
ALC: 850

Not documented

Not documented

WBC: 8,900
ALC: 950

1. Enlarged heart
2. Pulmonary infection
3. Pleural effusion
Not documented

1. Hyponatremia
2. Hypochloremia
3. AKI
4. Metabolic acidosis
5. Elevated lactate
6. Transaminitis
1. ESR 46 mm/hr
2. CRP 11.85 mg/dL
3. D-dimer 1,068 ng/
mL DDU
4. Procalcitonin
8.16 ng/mL
5. Ferritin
66,165 ng/mL
6. LDH 3,332 U/L
1. hsT 544 ng/L
2. CK 2,135 U/L
3. CK-MB 54.3 ng/
mL

1. Increased ALT
2. Increased creatinine
3. Hematuria

Elevated lactate

1. Hyponatremia
2. Hypochloremia
3. Hyperkalemia

Not documented

Not documented

Not documented

1. CRP 54 ng/mL
CRP 1.3 mg/dL
2. D-dimer 166 ng/
mL (normal)
3. Ferritin 967mcg/L

Not documented

Not documented

1. tropI 11.37 g/L
2. Myoglobin
390.97 ng/mL
3. ntBNP 22,600pg/
mL
1. Sinus tachycardia
2. No ST-segment
elevation

tropI 7.9 ng/mL

Troponin T 225 ng/L
1. Troponin T
>10,000 ng/L
2. CK-MB 112.9 ng/L
3. BNP 21,025 ng/L.

Electrocardiogram

1. Sinus tachycardia
2. ST elevation in II,
III, aVF
3. ST depression in I,
aVL

Echocardiography

1. Severe global LV
dysfunction
2. Enlarged RV
3. RV dysfunction
4. Moderate-large
pericardial effusion
5. Intermittent RV
impaired ﬁlling &
collapse (s/o
tamponade)

1. Enlarged LV
2. Diffuse myocardial dyskinesia
3. Low LVEF (32%)
4. Pulmonary HTN
(44 mmHg)

Cardiac catheterization ﬁndings

Normal coronary
vasculature

Not performed

Diagnosis

NP-PCR

PCR on sputum,
BALF

1. hST 0.24 ng/mL
2. CK-MB 20.3 ng/
mL
3. ntBNP 5,647pg/
mL
1. Sinus tachycardia 1. Low voltage in
limb leads
2. Low voltage QRS
complexes in limb 2. Minimal diffuse
ST elevation
leads
(more prominent in
3. ST elevation in I,
inferior & lateral
II, aVL, V2-V6
leads)
4. PR elevation & ST
depression in aVR 3. ST depression
with T-wave
inversion in V1,
aVR
1. Increased LV wall
1. Small LV
thickness
2. Severe concentric
2. Diffuse LV hypoLV hypertrophy
kinesis
3. Low LVEF (30%)
3. Low LVEF (40%)
4. Dilated, severely
4. Mildly impaired
hypokinetic RV
LV diastolic func5. Small circumfertion
ential pericardial
5. Circumferential
effusion
pericardial effusion (without s/o
tamponade)
Normal coronary
Non-obstructive
vasculature
coronary artery
disease
NP-PCR
NP-PCR

Case 6
47/F
Previous
myocarditis
Unknown

Not documented

ST elevation in III,
aVF

1. Sinus tachycardia
2. Concave ST elevation in infero-lateral leads

1. Enlarged heart
2. Marked decrease
in LV systolic
function
3. Low LVEF (27%)
4. Trace pericardial
effusion

1. Normal LV function
2. Global pericardial
effusion (without
s/o tamponade)

Normal coronary
vasculature

Not performed

NP-PCR

NP-PCR

(continued)
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Management

Secondary
infections

Outcome

Reference

1. MV
2. Pericardiocentesis
3. Vasopressors
4. Inotropes
5. HCQ
6. Azithromycin
7. Vancomycin
8. Cefepime
9. IVIG
10. MP
11. Methylene blue
No

Death
(4th DOHS)

Current case

1. MV
2. Vasopressors
3. Lopinavir-ritonavir
4. Interferon a-1b
5. MP
6. IVIG
7. Piperacillin-tazobactam
8. CRRT
9. ECMO
1. Candida (BALF)
2. Human a-herpesvirus and b-herpesvirus (BALF)
3. Bacteroides ovalus
(blood cultures)
Death
(33rd DOHS)

[14]

1. IABP
2. Inotropes
3. HCQ

1. Inotropes
2. HCQ
3. Lopinavir-ritonavir
4. IV Aspirin
5. MP
6. Diuretics
7. Beta-blockers

1. Vasopressors
2. Inotropes
3. IVIG
4. MP
5. Piperacillin-tazobactam
6. Diuretics

1. Vasopressors
2. Pericardiocentesis

No

No

No

No

Recovery
(7th DOHS still
hospitalized)

Recovery
(6th DOHS
unclear if still
hospitalized)
[16]

Recovery
(7th DOHS
unclear if still
hospitalized)
[17]

Recovery

[15]

Pericardiocentesis was performed and 600cc of serosanguinous
ﬂuid was drained, with the drain left in place. Pericardial ﬂuid studies
revealed 69 nucleated cells (6% granulocytes, 31% lymphocytes, 48%
monocytes, 11% mesothelial cells, 4% reactive mesothelial cells). TTE
performed post-pericardiocentesis revealed moderate improvement
in hemodynamic parameters.
The patient was transferred to the intensive care unit (ICU) from
the CCL. The working diagnosis was SARS-Cov-2 infection causing
purulent myopericarditis, leading to cardiogenic and distributive
shock, with multi-organ failure (transaminitis, lactic acidosis, metabolic acidosis and acute kidney injury) and possibility of bacterial coinfection. He was started on intravenous (IV) inotrope (dobutamine),
IV vasopressors (vasopressin, norepinephrine), enteral hydroxychloroquine (400 mg every 12 h on day one, followed by 200 mg every
12 h for 8 doses), IV azithromycin, IV cefepime and IV vancomycin.
He was evaluated by the Infectious Diseases service. Due to multiorgan failure (vasopressor support, elevated transaminases) and suspected bacterial co-infection, he was not eligible for investigational
immunosuppressive therapies. The presence of acute kidney injury
excluded enrollment in the antiviral Remdesivir trial. The heart failure and nephrology services actively assisted in his care.
Intravenous immunoglobulin (IVIG) was started (20 mg/kg/
dose) on hospital day two, with increasing pressor requirements.
He was noted to have melena on hospital day three, with further
increase in vasopressor support
epinephrine IV infusion, methylene blue IV infusion and IV methylprednisolone (200 mg/d IV)
were subsequently added. Cardiothoracic surgery was consulted
for extracorporeal membrane oxygenation (ECMO) therapy, but it
was not initiated due to evidence of gastro-intestinal bleeding
and multi-organ failure.
Cytologic analysis of pericardial ﬂuid revealed reactive mesothelial cells. Pericardial ﬂuid cultures revealed no growth of bacteria,
acid-fast bacilli or viruses. Blood cultures revealed no bacterial
growth. He had worsening hemodynamics, with concomitant worsening laboratory parameters (peak AST 2567 U/L; peak ALT 997 U/L;
peak creatinine 4.37 mg/dL and peak lactate 13.3 mmol/L) and lymphocyte counts [CD4+ 148/mL (18%); CD8+ 48/mL (6%)]. He succumbed to multi-organ failure on hospital day four, despite maximal
vasopressor support and supportive care.
Discussion
SARS-Cov-2 exists in a different clade from other b-Coronaviruses
severe-acute-respiratory-syndrome-coronavirus (SARS-Cov) and Middle-East-respiratory-syndrome-coronavirus (MERS-Cov) .3 Both SARSCov and MERS-Cov have been associated with myocardial injury,

(unclear if still
hospitalized)
[18]

myocarditis, and heart failure.5 7 Additionally, comorbidities like diabetes mellitus (DM) and hypertension in these patients were associated
with increased mortality.8,9
A recent meta-analysis found that the prevalence of hypertension,
cardiac/cerebrovascular disease and DM in Covid-19 patients was
17.1%, 16.4%, and 9.7%, respectively.10 Patients needing ICU admission
were also more likely to have these comorbidities.10 Covid-19
patients with these comorbidities also had higher mortality rates.11
A spectrum of cardiac complications [myocarditis, heart failure, cardiac arrhythmias, myocardial infarction (MI)] are being increasingly
reported in Covid-19 patients.3,4,12,13 A higher incidence of complications [acute respiratory distress syndrome (ARDS), malignant
arrhythmias, AKI] and higher mortality rates were seen in Covid-19
patients with myocardial injury.13
There have been few well-described case reports of SARS-Cov-2
causing focal myocardial and/or pericardial involvement14 18
(Table 1). Like our patient, they had elevated cardiac markers, with
ECG changes and signs of ventricular dysfunction. Two patients had
predominant symptoms of ACS without viral symptoms15,17
this
correlates with reports of Covid-19 presenting with predominantly
cardiovascular symptoms in some patients.19 Despite their presentation, no signiﬁcant ﬁndings were noted in those who underwent cardiac catheterization. Different treatment regimens were instituted
however, apart from our case, one other patient expired.14
Our patient, like other cases,14,17 met several criteria for fulminant myocarditis. These include acuity of onset; premonitory
symptoms of viral infection; rapidly developing severe hemodynamic dysfunction; evidence of severe myocardial injury & diffuse
decreased ventricular wall movement; and symptoms of injury to
other organs.20 The reported mortality rate of this rare syndrome
is between 40 70%.21 The current management of viral myocarditis involves use of immunomodulatory therapy (steroids, IVIG);
supportive therapy (including mechanical ventilation); and circulatory assist devices (Impella heart pump, intra-aortic balloon
pump) to reduced wall stress and inﬂammation.20,22 The role of
ECMO and continuous renal replacement therapy (CRRT) in
Covid-19 is unclear. It may help remove circulating cytokines and
increase blood oxygen saturation, reducing the immune response
and further reducing myocardial damage.14 ECMO therapy has
been useful in some Covid-19 patients with cardiogenic shock,15
but more data is needed. It is unclear at this time what factors
contribute to increased mortality in Covid-19 patients with myocarditis. Worse outcomes have been noted in those with co-infections.12 In one case, worsening of certain hemodynamic
parameters (such as pulmonary artery systolic pressure) indicate
functional decline and may help as markers of mortality.14
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The exact mechanism of SARS-Cov-2-induced cardiac injury is not
yet known. There are different theories:
(a) Direct injury by viral replication. SARS-Cov has been detected in the
heart on autopsy.23 One study documented the concurrent presence
of a high SARS-Cov-2 viral load in patients with fulminant myocarditis.24 However, autopsies of Covid-19 patients revealed mononuclear cell inﬂammatory inﬁltrates without viral inclusions.25
(b) Exaggerated and dysregulated immune response (“cytokine
storm”) seen with other coronavirus infections. This leads to
increased vascular permeability, cell apoptosis, suboptimal T-cell
and antibody responses and ARDS.26 Higher levels of inﬂammatory markers were noted in Covid-19 patients in the ICU.27 Additionally, a concomitant rise in cardiac markers and other
inﬂammatory markers seen in Covid-19 patients (some of whom
eventually died) supports this hypothesis.4,11,13,21
(c) Hypoxia (due to SARS-Cov-2-induced ARDS) can lead to inﬂammation, cell injury and subsequent cardiac damage.28 It can also lead to
increased intracellular calcium deposition and apoptosis.19
(d) Systemic inﬂammation potentiating localized inﬂammation in
advanced atherosclerotic coronary vessels has been seen in other
viral illnesses.29 Lymphopenia3,27 has been noted in Covid-19
patients and has previously been linked to the development of
atherosclerosis.30
(e) Direct myocardial involvement mediated via Angiotensin-converting-enzyme-2 (ACE2). ACE2 is an endothelium-bound
enzyme that converts angiotensin I & II to inactive metabolites.31
Its expression was necessary for pulmonary infection by SARSCov.32 In murine models, SARS-Cov precipitated an ACE2-dependent MI after pulmonary infection.23
Our patient was diagnosed with a purulent myopericarditis and
tamponade, causing circulatory shock with fatal multi-organ failure.
His clinical picture, radiographic and laboratory ﬁndings ﬁt the diagnosis of Covid-19. There were no other identiﬁed causes of myopericarditis. The rapidity of disease progression, combined with ﬁndings
of purulent myopericarditis (previously unreported in the literature)
contributes to the unique presentation of our case.
Conclusion
In the current pandemic scenario, clinicians must keep SARSCov-2 infection in the differential of patients presenting with
acute coronary syndromes and ﬁndings of purulent myopericarditis, cardiac tamponade and circulatory shock. Further research is
needed to deﬁne the optimal management of such complex clinical scenarios.
Declaration of Competing Interest
None
Both authors declare that they have no pertinent conﬂicts of interest.
Acknowledgements
The authors gratefully acknowledge Sonia Henry, MD, FACC for
her assistance in interpretation of the echocardiographic images.
This research did not receive any speciﬁc grant from funding
agencies in the public, commercial, or not-for-proﬁt sectors.
References
1. World Health Organization. Emergency preparedness, response: disease outbreak
news: update
12 th January2020. Available Online:https://www.who.int/csr/
don/12-january-2020-novel-coronavirus-china/en/(Accessed April 14, 2020).

5

2. World Health Organization. Coronavirus disease (COVID-2019) press brieﬁngs
- 11 March2020. Available Online:https://www.who.int/emergencies/diseases/
novel-coronavirus-2019/media-resources/press-brieﬁngs (Accessed April 13,
2020).
3. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with
2019 novel coronavirus-infected pneumonia in Wuhan. China JAMA.. 2020. https://
doi.org/10.1001/jama.2020.1585.
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020.
https://doi.org/10.1016/S0140-6736(20)30566-3.
5. Li SS, Cheng CW, Fu CL, et al. Left ventricular performance in patients with
severe acute respiratory syndrome: a 30-day echocardiographic follow-up
study. Circulation. 2003;108(15):1798–1803. https://doi.org/10.1161/01.
CIR.0000094737.21775.32.
6. Chong PY, Chui P, Ling AE, et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS
diagnosis. Arch Pathol Lab Med. 2004;128(2):195–204. https://doi.org/10.1043/
1543-2165(2004)128<195:AODDTS>2.0. CO;2.
7. Alhogbani T. Acute myocarditis associated with novel middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016;36(1):78–80. https://doi.org/10.5144/
0256-4947.2016.78.
8. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA.
2003;289:2801–2809. https://doi.org/10.1001/jama.289.21.JOC30885.
9. Badawi A, Ryoo SG. Prevalence of comorbidities in the middle east respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect
Dis. 2016;49:129–133.
10. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020. https://doi.org/10.1007/
s00392-020-01626-9. [Preprint].
11. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with
coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. https://doi.
org/10.1136/bmj.m1091.
12. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality
due to COVID-19 based on an analysis of data of 150 patients from Wuhan,
China. Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-05991x.
13. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiology. Published online;
2020. https://doi.org/10.1001/jamacardio.2020.0950.
14. Zeng J.H., Liu Y., Yuan J. et al. First Case of COVID-19 complicated with fulminant
myocarditis: a case report and insights. Preprints [Preprint]. 2020, 2020030180.
doi:10.1007/s15010-020-01424-5.
15. Fried JA, Ramasubbu K, Bhatt R, et al. The variety of cardiovascular presentations of
COVID-19. Circulation. 2020;141(23):1930–1936. https://doi.org/10.1161/CIRCULATIONAHA.120.047164.
16. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement 1 with coronavirus 2019
(COVID-19) infection. JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1096.
17. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020. https://doi.org/10.1093/
eurheartj/ehaa190. ehaa190.
18. Hua A, O'Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020. https://doi.org/10.1093/
eurheartj/ehaa253. [Preprint]pii: ehaa253.
19. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat
Rev Cardiol. 2020. https://doi.org/10.1038/s41569-020-0360-5. [Preprint].
20. Wang D, Li S, Jiang J, et al. Chinese society of cardiology expert consensus
statement on the diagnosis and treatment of adult fulminant myocarditis.
Sci China Life Sci. 2019;62(2):187–202. https://doi.org/10.1007/s11427-0189385-3.
21. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020. https://doi.org/10.1007/s00059-020-04909-z.
[Preprint].
22. Kociol RD, Cooper LT, Fang JC, et al. Recognition and initial management of fulminant myocarditis: a scientiﬁc statement from the American Heart Association. Circulation.. 2020. https://doi.org/10.1161/CIR.0000000000000745.
23. Oudit GY, Kassiri Z, Jiang C, et al. SARS coronavirus modulation of myocardial ACE2
expression and inﬂammation in patients with SARS. Eur J Clin Invest..
2009;39:618–625. https://doi.org/10.1111/j.1365-2362.2009.02153.x.
24. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci.
2020;63:364–374. https://doi.org/10.1007/s11427-020-1643-8.
25. Xu Z, Shi L, Wang Y C, et al. Pathological ﬁndings of COVID-19 associated with
acute respiratory distress syndrome. Lancet Respir Med.. 2020. https://doi.org/
10.1016/S2213-2600(20)30076-X.
26. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes
and consequences of cytokine storm and immunopathology. Semin Immunopathol..
2017;39(5):529–539. https://doi.org/10.1007/s00281-017-0629-x.
27. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
coronavirus in Wuhan. China Lancet.. 2020. https://doi.org/10.1016/S0140-6736
(20)30183-5.
28. Wu J, Stefaniak J, Hafner C, et al. Intermittent hypoxia causes inﬂammation and
injury to human adult cardiac myocytes. Anesth Analg. 2016;122(2):373–380.
https://doi.org/10.1213/ANE.0000000000001048.

ARTICLE IN PRESS
6

A. Khatri and F. Wallach / Heart & Lung 00 (2020) 1 6

29. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering
acute coronary syndromes. Lancet Infect Dis. 2010;10(2):83–92. https://doi.org/
10.1016/S1473-3099(09)70331-7.
30. Nunez J, Sanchis J, Bodi V, et al. Relationship between low lymphocyte count and
major cardiac events in patients with acute chest pain, a non-diagnostic electrocardiogram and normal troponin levels. Atherosclerosis.. 2009;206:251–257.
https://doi.org/10.1016/j.atherosclerosis.2009.01.029.

31. Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med. 2003;13:93–101. https://doi.org/10.1016/
s1050-1738(02)00233-5.
32. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2
(ACE2) in SARS coronavirus induced lung injury. Nat Med. 2005;11:875–879.
https://doi.org/10.1038/nm1267.

